Nuclear Transport Checkpoint Inhibitors for Skin Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis only partially inhibit inflammatory signaling, leading to refractoriness or relapse, and are associated with significant side effects such as hyperglycemia, hyperlipidemia, osteoporosis, and skin atrophy.
Innovation Solution
The use of Nuclear Transport Checkpoint Inhibitors (NTCIs), also known as Nuclear Transport Modifiers (NTMs), which target importins α5 and β1 to inhibit the nuclear translocation of stress-responsive transcription factors and metabolic transcription factors, thereby reducing inflammatory responses and associated metabolic derangements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad spectrum therapy with glucocorticoids is used, then inflammatory signaling is inhibited, but metabolic side effects occur including hyperglycemia,hyperlipidemia,osteoporosis, and skin atrophy
Solution Approach 1:
The invention segments the broad anti-inflammatory effect into targeted inhibition of specific transcription factors (NF-κB, AP-1, NFAT, STAT) that mediate inflammatory signaling. By using small molecule inhibitors that selectively block these transcription factors, the therapy achieves effective anti-inflammatory action while avoiding the metabolic side effects associated with glucocorticoid binding to the nuclear receptor.
Solution Approach 2:
The invention introduces small molecule inhibitors as intermediaries that selectively bind to and inhibit specific transcription factors involved in inflammatory signaling. These intermediaries (small molecule inhibitors) provide targeted suppression of inflammatory pathways without triggering the broad metabolic effects of glucocorticoids, thus resolving the contradiction between effective inflammation control and metabolic safety.
2Object-affected harmful factors
If targeted therapies with monoclonal antibodies or small molecule inhibitors are used, then specific inflammatory mediators are blocked, but refractoriness or relapse occurs due to untargeted mediators
Solution Approach 1:
The invention employs small molecule inhibitors that can simultaneously target multiple transcription factors (NF-κB, AP-1, NFAT, STAT) involved in inflammatory signaling. This multi-functional approach allows a single therapeutic agent to inhibit multiple inflammatory pathways at the transcriptional level, preventing refractoriness or relapse that occurs with single-target therapies while maintaining treatment persistence.
Solution Approach 2:
The invention changes the therapeutic parameter from targeting individual cytokines or receptors (monoclonal antibodies) to targeting transcription factors that control the expression of multiple inflammatory mediators. This parameter change enables broader and more sustained inhibition of inflammatory signaling, addressing the relapse issue associated with narrow-target therapies.
3Reliability
If current anti-inflammatory therapies are used, then some inflammatory pathways are suppressed, but the complexity of multiple inflammatory mediators requires multiple targets
Solution Approach 1:
The invention merges multiple anti-inflammatory mechanisms into a unified approach by using small molecule inhibitors that simultaneously suppress multiple transcription factors (NF-κB, AP-1, NFAT, STAT). This consolidation allows comprehensive inhibition of inflammatory pathways through a single class of agents, reducing the complexity of requiring multiple separate therapies or targets while maintaining reliable anti-inflammatory suppression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
NTCIs effectively reduce the expression of genes encoding mediators of skin inflammation, leading to decreased inflammation, improved treatment outcomes, and minimized side effects compared to existing therapies.
Implementation Method 1
Nuclear Transport Checkpoint Inhibitors (NTCIs), also known as Nuclear Transport Modifiers (NTMs), which target importins α5 and β1 to inhibit the nuclear translocation of stress-responsive transcription factors
Data Source
AI summary
Disclosed are methods for assessing the responsiveness of a patient to a Nuclear Transport Checkpoint Inhibitor (NTCI) as well as the efficacy of a NTCI treatment regimen. Additionally disclosed herein are methods of genomic diagnosing a subject with an inflammatory skin disease.